Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » ArcherDx, Illumina Agree to Comarket Future IVDs

ArcherDx, Illumina Agree to Comarket Future IVDs

Jan 10, 2020
|
staff reporter

NEW YORK – ArcherDx said on Friday that it has signed a non-exclusive, multiyear partnership with Illumina intended to broaden access to next-generation sequencing oncology testing, including — upon regulatory approval — companion diagnostics for therapeutic selection, personalized monitoring, and new recurrence surveillance in vitro diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

What's Popular?

In Business News

  1. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  2. Catalog DNA Merges Molecular Biology, Information Theory to Pursue DNA-Based Computing

    Premium

  3. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  4. Ionpath Expanding Sales Force, Investing in Informatics Tools Development

    Premium

  5. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.